The Emergent BioSolutions manufacturing plant in East Baltimore that has been making coronavirus vaccine for months has not yet received emergency use authorization from the federal government, a ...
Emergent BioSolutions stopped production in April. The Food and Drug Administration is close to authorizing Emergent BioSolutions’ Baltimore facility to produce Covid-19 vaccine, the Wall Street ...
The report sheds new light on executives’ worries about deficiencies in the company’s quality control systems at its troubled Baltimore plant; no contaminated doses were ever released to the public.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback